Related Experiment Video

Updated: Sep 1, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Recombinant human erythropoietin as a treatment for anemia of prematurity

P Downey1

  • 1Swedish Health Services, Seattle, Washington, USA.

The Journal of Perinatal & Neonatal Nursing
|February 6, 1998
PubMed

Insights

Recombinant human erythropoietin effectively treats anemia of prematurity (AOP) by boosting red blood cell production. Studies show it reduces transfusion needs and improves hematocrit in premature infants.

Area of Science:

  • Neonatal Medicine
  • Hematology

Background:

  • Anemia of prematurity (AOP) is a heightened physiological anemia in infants.
  • Inadequate erythropoietin production is the main cause of AOP.
  • Erythropoietin regulates red blood cell production.

Purpose of the Study:

  • To evaluate the safety and efficacy of recombinant human erythropoietin (rHuEPO) in treating AOP.

Main Methods:

  • Studies assessed rHuEPO's impact on hematocrit and reticulocyte counts.
  • Transfusion data and iron levels were analyzed.

Main Results:

  • Consistent increases in hematocrit and reticulocyte counts were observed.
  • Fewer blood transfusions and reduced transfusion volumes per kilogram were noted.
  • A decrease in bioavailable iron was documented.

Conclusions:

  • Recombinant human erythropoietin is safe and effective for managing AOP.
  • Current dosing recommendations are 200 U/kg daily or every other day via subcutaneous or intravenous routes.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Related Concept Videos

Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...